To our knowledge, this is the first case report of a typical carcinoid tumor-associated spontaneous massive hemothorax in the literature. Herein, we discuss the diagnosis of this rare condition and present a review of the literature.
The patient, who did not have any additional diseases and did not use drugs, had no history of smoking. In a thorax CT scan taken in 2010, a 25¥20 mm oval and well-circumscribed hypodense nodule localized in the right upper lobe was observed, and it was radiologically followed for two years (Figure 3). In this period, no progression was observed in the lesion, and no diagnostic intervention was performed. The lesion, considered to be a hamartoma, was not followed radiologically in the following years.
At the physical examination, the patient had a blood pressure of 120/80 mmHg, a rhythmic pulse of 108/min, a body temperature of 36.1°C, a respiratory rate of 20/min, mild dyspnea, and the breathing sounds could not be obtained from the right hemithorax in the auscultation. Heart sounds were normal, rhythmic, and tachycardic.
Laboratory parameters were as follows: hemoglobin, 9.8 g/dL, hematocrit, 29.8%; red blood cell count, 3.32 106/uL; white blood cell count, 12,600/mm3; platelet count, 334,000/mm3; C-reactive protein, 30.21 mg/dL; glucose, 130 mg/dL; blood urea nitrogen, 18 mg/dL; creatinine, 0.96 mg/dL; sodium, 138 mEq/L; potassium, 4.4 mEq/dL; calcium, 7.8 mg/dL; aspartate aminotransferase, 17 U/L; alanine aminotransferase, 22 U/L; lactate dehydrogenase, 330 U/L; ferritin, 179.9 ng/mL; troponin I, 0.01 ng/mL; D-dimer, 1,848 ng/mL; prothrombin time, 13.7 s; international normalized ratio, 1.13. Blood gas test values were as follows: pH, 7.52; pCO2, 31.5 mmHg; pO2, 57.8 mmHg; saturation, 92.9%. Pleural fluid values were as follows: hemoglobin, 4.3 g/dL; hematocrit, 14.2%; lactate dehydrogenase, 230 U/L; glucose, 55 mg/dL. Meanwhile, the COVID-19 PCR test was reported as negative.
In the positron emission tomography (PET/CT) taken after tube thoracostomy, a 60¥55 mm hypodense lesion in the right upper lobe posterior segment with minimal fluorine-18-fluorodeoxy-D-glucose (FDG) involvement (maximum standardized uptake value [SUVmax]: 2.9) was observed at the periphery, while pleural fluid with 63 mm thickness (SUVmax: 2.4) was detected in the right hemithorax (Figure 4). Metastasis was not observed in the brain magnetic resonance imaging.
The clinically stabilized patient underwent fiberoptic bronchoscopy and right posterolateral thoracotomy under general anesthesia the next day. The endobronchial lesion was not observed in fiberoptic bronchoscopy. The thoracotomy revealed a defibrinated hematoma in the thorax and a 60¥50 mm cavitary lesion with a hematoma in the right upper lobe. After cleaning inside the cavity, an incisional biopsy was taken from the lung parenchyma that seemed to be suspicious, and a frozen section analysis was carried out. Upon pathology report stating malignancy, right upper lobectomy and mediastinal lymph node dissection were performed. The patient was discharged on the sixth day with an uneventful postoperative follow-up. Histopathological examination of the lobectomy material revealed a typical carcinoid tumor (T2bN0M0, Stage IIA), and no metastatic lymph node was observed (Figure 5).
Bronchial carcinoids are tumors from a wide spectrum of neuroendocrine tumors, including typical and atypical carcinoid tumors, large cell neuroendocrine carcinoma, and small cell lung cancer. It accounts for 1 to 2% of all lung cancers, and 85% are localized in the central region (main bronchus or lobe bronchi). It depends on the size of the clinical tumor and its location in the peripheral or central area. Peripherally located tumors are usually asymptomatic, and they are detected incidentally. The tumors located in the central region usually present with symptoms related to airway irritation, such as cough and hemoptysis, and obstruction, as in recurrent pulmonary infections.[3]
In radiological evaluation, particularly in thorax CT scans, centrally located carcinoid tumors are observed to be well-defined margins and hypervascular tumors, while the peripherally located ones are observed as solitary pulmonary nodules.[3] Therefore, peripherally localized tumors, as in our case, have the potential to cause a spontaneous hemothorax, except for the symptom associated with bronchial obstruction. Carcinoid tumors are hypervascular tumors, and they show variable SUVmax v alues d epending on the proliferation and mitosis of the tumor in PET/CT. In our case, the peripherally located mass caused visceral pleural invasion and ruptured into the pleural cavity, leading to the development of hemothorax. The fact that the SUVmax value of the mass is measured as 2.9 in PET/CT indicates that the tumor is highly necrotic, and the number of viable cells in the mass is low.
Tumor-related hemothorax mechanism is defined as the invasion and ischemic necrosis of the visceral pleura and lung parenchyma by the tumor tissue, causing the rupture of the parenchymal vessels into the pleural cavity.[1,5] In our case, the solitary pulmonary nodule localized in the right upper lobe, which was radiologically detected approximately 10 years ago, became a mass over the years, and massive hemothorax developed as a result of the visceral pleural invasion and bleeding into the pleural cavity.
The prognosis is poor in cases of cancer-related hemothorax.[1] However, in bronchial carcinoid tumors, the prognosis will be excellent with the surgical treatment performed after the patient's clinic is stabilized. Ordinarily, lobectomy is preferred as the treatment method for bronchial carcinoid tumors, and the five-year survival rate for localized diseases without lymph node metastasis is 90%.[3]
In conclusion, spontaneous hemothorax associated with lung cancer is an exceedingly rare condition, with no previous cases caused by the rupture of atypical bronchial carcinoid tumors in the literature. It should be kept in mind that the underlying disease in patients, although is rare, might be typical carcinoid with a mass in the lung and a developing spontaneous massive hemothorax clinic.
Patient Consent for Publication: A written informed consent was obtained from the patient.
Data Sharing Statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.
Author Contributions: Conception, design, data collection and analysis, literature review, writer - B.Ç.; Conception, design, data collection and analysis, critical review - H.U.Ç.; Design, data collection and analysis, literature review, critical review - H.K.Ç.
Conflict of Interest: The authors declared no conflicts of interest with respect to the authorship and/or publication of this article.
Funding: The authors received no financial support for the research and/or authorship of this article.
1) Patrini D, Panagiotopoulos N, Pararajasingham J, Gvinianidze
L, Iqbal Y, Lawrence DR. Etiology and management of
spontaneous haemothorax. J Thorac Dis 2015;7:520-6.
2) Hsu NY, Shih CS, Hsu CP, Chen PR. Spontaneous hemopneumothorax revisited: Clinical approach and
systemic review of the literature. Ann Thorac Surg
2005;80:1859-63b
3) Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer
M, et al. Pulmonary carcinoid: Presentation, diagnosis, and
outcome in 142 cases in Israel and review of 640 cases from
the literature. Chest 2001;119:1647-51.